Clinical data | |
---|---|
Routes of administration | Nasal |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C13H19NO2 |
Molar mass | 221.300 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
PF-219,061 is a drug that was under development by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor. [1] [2] It was under development as a potential medication for the treatment of female sexual dysfunction. [3] [4] It did not advance into clinical trials. [5]
Clinical data | |
---|---|
Routes of administration | Nasal |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C13H19NO2 |
Molar mass | 221.300 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
PF-219,061 is a drug that was under development by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor. [1] [2] It was under development as a potential medication for the treatment of female sexual dysfunction. [3] [4] It did not advance into clinical trials. [5]